On Nov. 25, 2020, Moderna announced that the European Commission (EC) has approved an agreement to secure 80 million doses of mRNA-1273, Moderna’s vaccine candidate against COVID-19, as part of the ECﾒs goal to secure access to a safe and effective COVID-19 vaccine for Europe.

The EC had the option to increase their purchase of mRNA-1273, from 80 million doses to a total of up to 160 million doses.